On October 29, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated medical technology company, announced preliminary unaudited revenue results for its fiscal first quarter ending September 30, 2024. The company reported an increase in revenue of approximately $0.87 million, marking a 10% rise year-on-year and a 20% increase quarter-on-quarter. Intelligent Bio Solutions highlighted the growing importance of its cartridge sales, which are expected to become the primary revenue driver due to their higher profit margins and recurring nature. The company's Intelligent Fingerprinting Drug Screening System, which utilizes these cartridges, is gaining traction with over 400 active customer accounts, signaling confidence in the product and contributing to a steady stream of recurring revenue. Additionally, the company has expanded its distribution network in Saudi Arabia, aiming to meet the increasing global demand for drug testing solutions. The full financial results for the quarter will be disclosed in the upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in the week commencing November 4, 2024.

On October 29, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated medical technology company, announced preliminary unaudited revenue results for its fiscal first quarter ending September 30, 2024. The company reported an increase in revenue of approximately $0.87 million, marking a 10% rise year-on-year and a 20% increase quarter-on-quarter. Intelligent Bio Solutions highlighted the growing importance of its cartridge sales, which are expected to become the primary revenue driver due to their higher profit margins and recurring nature. The company's Intelligent Fingerprinting Drug Screening System, which utilizes these cartridges, is gaining traction with over 400 active customer accounts, signaling confidence in the product and contributing to a steady stream of recurring revenue. Additionally, the company has expanded its distribution network in Saudi Arabia, aiming to meet the increasing global demand for drug testing solutions. The full financial results for the quarter will be disclosed in the upcoming Quarterly Report on Form 10-Q, to be filed with the SEC in the week commencing November 4, 2024.